MUMBAI, India, Oct. 5 -- Intellectual Property India has published a patent application (202618109492 A) filed by Regeneron Pharmaceuticals, Inc. on September 11, 2026, for Human Antibodies To Ebola Virus Glycoprotein.
Inventors include Kyratsous, Christos; Olson, William; Mason, Peter; and Stahl, Neil.
The application for the patent was published on October 02, 2026, under issue no. 40/2026.
Abstract: ABSTRACT HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN The present invention provides monoclonal antibodies, or antigen-binding 5 fragments thereof, that bind to Ebola virus glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing Ebola virus activity, thus providing a means of treating or preventing Ebola virus infection in humans. In some embodiments, the invention provides for use of one or more antibodies that 10 bind to the Ebola virus for preventing viral attachment and/or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines. 15 89
Disclaimer: Curated by HT Syndication.
